OrbiMed Advisors Buys $10M in BlossomHill IPO at $16.00
BLSM is trading near its 52-week low of $15.97 (1.7% above the low).
Summary
OrbiMed Advisors LLC, a director-affiliated entity, bought $10 million of BlossomHill Therapeutics stock in the IPO at $16.00 per share, a significant insider purchase.
Key Events · Ownership and Investor Activity · BLSM
-
OrbiMed Buys $10M in IPO
OrbiMed Advisors LLC purchased 625,000 shares at $16.00 per share for a total of $10,000,000 in BlossomHill's initial public offering on August 10, 2026.
-
Preferred Stock Conversion
OrbiMed converted 2,089,279 shares of Series A and Series B Preferred Stock into common stock upon the IPO closing, with no additional consideration paid.
-
Post-Transaction Holdings
After the purchase and conversion, OrbiMed's indirect holdings total 2,714,279 shares, representing a significant stake in the newly public company.
-
Insider Accumulation Signal
This purchase adds to the accumulation signal from other insiders, including Cormorant Asset Management's $5 million purchase and the General Counsel's $74,700 purchase, all at the IPO price.
Analysis · BLSM · Life Sciences
A director-affiliated entity, OrbiMed Advisors LLC, purchased 625,000 shares for $10 million in BlossomHill's IPO at $16.00 per share. This is a significant open-market purchase by a key insider, representing roughly 2% of the company's market cap. The purchase follows the IPO pricing on August 7 and closing on August 10, and adds to the accumulation signal from other insiders. OrbiMed also converted 2,089,279 preferred shares into common stock upon the IPO, increasing its post-transaction holdings to 2,714,279 shares.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLSM was trading at $16.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $497.7M. The 52-week trading range was $15.97 to $17.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.